drugset / Trial / NCT01550003
Pediatric Arthritis Study of Certolizumab Pegol
NaSingle-groupOpen-labelTreatment
Summary
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
Timeline
- Start
- 2012-03-08
- Primary completion
- 2024-04-08
- Completion
- 2024-04-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 50 mg | Subcutaneous |
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 100 mg | Subcutaneous |
| Subject | Certolizumab Pegol | Protein / enzyme biologic | 200 mg | Subcutaneous |